To vet potential investors or acquirers, founders should ask them to articulate their vision for the startup's next five years. Hearing their story told through the buyer's eyes reveals the depth of their strategic thinking and helps assess whether their vision aligns with the founder's, ensuring a better post-transaction fit.

A stated M&A strategy is only a hypothesis. To validate it, present the leadership team with actual potential targets that fit the criteria. Their reactions will reveal their true appetite and expose any misalignment between the written strategy and their operational instincts, saving time and effort.

A successful exit is a highly choreographed dance, not an abrupt decision. Founders should spend years building relationships with line-of-business leaders—not just Corp Dev—at potential acquiring companies. The goal is to 'incept' the idea of an acquisition long before it's needed.

The shift to a nonprofit was a strategic decision to create an incentive structure that prioritizes maximizing educational impact over profit. This move prevents future leaders from pivoting to more lucrative but less mission-aligned business models like freemium services or selling to EdTech companies.

Founders who wait until they need to sell have already failed. A successful exit requires a multi-year 'background process' of building relationships. The key is to engage with SVPs and business unit leaders at potential acquirers—the people who will champion the deal internally—not just the Corp Dev team who merely execute transactions.

When a potential acquirer calls, the founder's default mode should be information gathering, not pitching. By asking strategic questions ("Who else are you talking to?", "What are your goals?"), founders can extract valuable competitive intelligence about the market and the larger company’s plans, regardless of whether a deal happens.

If a compelling target company doesn't align with your M&A framework, don't just kill the deal. Use it as a prompt to re-evaluate your strategy. The target might be a sign that your initial assumptions were flawed. The choice isn't just "yes/no" on the deal, but "is our strategy still right?".

To achieve a high-value acquisition, biotechs must first build a credible strategy to succeed independently, creating a position of strength. Concurrently, leaders should keep multiple potential suitors proactively informed on all business aspects—not just clinical data—to facilitate a competitive bidding process when the time comes.

Instead of jumping directly to an acquisition, de-risk the process by first establishing a partnership or licensing agreement. This allows you to test the technology, cultural fit, and market reception with a lower commitment, building a stronger foundation for a potential future deal.